Clinical Trials Logo

Influenza clinical trials

View clinical trials related to Influenza.

Filter by:

NCT ID: NCT03020537 Completed - Influenza Clinical Trials

B-cell Immunity to Influenza (SLVP017)- Year 5, 2013

Start date: October 2013
Phase: Phase 4
Study type: Interventional

In this exploratory study, investigators will be looking at immune response differences between age groups and between the two different vaccines given to identical twins and vaccine-naive young adults.

NCT ID: NCT03020498 Completed - Influenza Clinical Trials

B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)

Start date: September 2010
Phase: Phase 4
Study type: Interventional

In this exploratory study, investigators will be looking at immune response differences between age groups and between the two different influenza vaccines given to identical twins and vaccine-naive young adults.

NCT ID: NCT03020472 Completed - Influenza Clinical Trials

Kinetics of B-Cell Responses to Live Attenuated Influenza Vaccine (LAIV) in Young Children Two Years of Age

SLVP016
Start date: November 2008
Phase: Phase 4
Study type: Interventional

This pilot study will investigate the peak of the post-immunization B-cell responses following vaccination with live, attenuated influenza vaccine in healthy children 2 years of age from blood samples taken at designated time points before and after vaccination.

NCT ID: NCT03016143 Completed - Influenza Clinical Trials

Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI)

Start date: October 2016
Phase: Phase 2
Study type: Interventional

The study is a single centre, phase II, double-blind, randomized, comparative trial that explored the immunogenicity and safety of single dose a allantoic split inactivated seasonal influenza vaccine and VAXIGRIP vacccine in healthy adults the two age groups (in persons 18 to 60 years of age and older than 60 years).

NCT ID: NCT03010410 Enrolling by invitation - Influenza Clinical Trials

Platelet Immune Responses in Aging and Influenza and Sepsis

Start date: December 2014
Phase: N/A
Study type: Observational

Aging is associated with immunosenescence and impaired host defense mechanisms, contributing to influenza-related morbidity and mortality. Preliminary data demonstrate that the platelet transcriptome is markedly different between healthy subjects and influenza patients. Interferon-induced transmembrane proteins (IFITM) family members are among the transcripts significantly increased in platelets during influenza and expression of IFITM-3 is impaired in elderly subjects, a pattern associated with increased mortality. This study will build on these data and investigate if aging influences the expression of platelet IFITM family members in patients with influenza and sepsis. This study will prospectively determine if aging alters the induction of (IFITMs) in platelets from hospitalized influenza and sepsis patients. The study will also determine if diminished expression of IFITM family members correlates with an increased risk of adverse outcomes in older influenza and sepsis patients.

NCT ID: NCT03010007 Not yet recruiting - Influenza Clinical Trials

Prospective Analysis of Seasonal Influenza - Viral Transmission and Evolution in the City of Basel, Switzerland

Start date: January 2017
Phase: N/A
Study type: Observational

Influenza associated illness has a global annual impact with high morbidity and mortality. Transmission mechanisms and rates are under-investigated and overall poorly understood. This project aims to use epidemiological tools to understand the transmission and evolution of influenza viruses at an individual and population level within a small-scale city (Basel) through a combination of experimental, clinical and mathematical advances. The investigators aim to quantitatively characterize the viral transmission using novel molecular-epidemiological tools based on whole genome sequencing.

NCT ID: NCT03004040 Recruiting - Influenza Clinical Trials

Protection From Influenza: Determining the Impact of Prior Infection

Start date: December 2016
Phase: N/A
Study type: Observational [Patient Registry]

The investigators propose a unique methodology of studying infection and vaccination history and immune responses. As most studies in infection history are conducted on mice, limitations are inherent on their applicability to humans. A longitudinal comparison study following older adults (over the age of 65) hospitalized for influenza are followed through to their hospital discharge and vaccination in the following season. This will allow for the investigation of the course of infection, as well as impact on the response to vaccination.

NCT ID: NCT02989194 Recruiting - Influenza Clinical Trials

Study of VIS410 in Subjects With Uncomplicated Influenza A

Start date: December 2016
Phase: Phase 2
Study type: Interventional

This is a Phase 2a randomized, double-blind, placebo-controlled study designed to assess the safety and tolerability of VIS410 in subjects with uncomplicated influenza.

NCT ID: NCT02987374 Completed - Influenza Clinical Trials

Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization

SLVP023
Start date: May 2012
Phase: Phase 4
Study type: Interventional

The purpose is to investigate B-cell response to the trivalent Influenza Vaccine (TIV) in healthy young adults. In particular, we will use unique strategies to study in detail the immune responses of immunoglobulins and antibody CDR3 before and after immunization.

NCT ID: NCT02983019 Completed - Influenza Clinical Trials

Treatment of Influenza in Routine Clinical Practice

FLU-EE
Start date: December 2013
Phase: N/A
Study type: Observational

This study evaluates the statistics of influenza and acute respiratory viral infections (ARVI) management in outpatient sites in Russia, Armenia, Moldova and Georgia (epidemiology: disease severity and bacterial exacerbations; patients demography; treatment duration and timelines; safety; quality of treatment) in routine clinical practice with focus on drug therapy and usage of interferons' inducers.